Stocks with good short-term prospects are more likely to manage volatility, which is expected to intensify amid multiple geopolitical and m...

Tata Motors is expected to report a net profit of between INR 3,100 to 3,204 crore and revenue growth of up to 34% for Q4 on the back of st...

Out of the 27 Nifty50 companies that have reported their quarterly numbers so far, 12 have reported results that beat Street expectations, ...

Margins remained pressured as companies deal with elevated attrition resulting in high retention costs and increase in travel and discretio...

Phillip Capital expects 8.1 per cent YoY growth in net profit of Cipla.

A difficult transformation is underway at Cipla, one of India’s largest and oldest pharma companies.

Nirmal Bang Securities sees 12.70 per cent year-on-year rise in net profit for Cipla in Q3 FY19 on 7 per cent.

Brokerage firm Sharekhan expects domestic loan growth of SBI to improve.

Here is a list of top stocks that are likely to be in focus in today's trading session.

The GST rollout has impacted the primary sales of pharma companies in the domestic market and aggravated their overall performance.

The biggest play is going to be over a longer period of time all those Indian corporates who have ventured into the defence after the polic...

The companies in the 50-share Nifty index may report a 17.6% year-on-year growth in operating profit for the third quarter - the best in si...

CIPLA is expected to report a 34% YoY increase in its Q4 net profit at Rs 286 crore compared to Rs 214 crore in the year ago period, accord...

ET NOW Fundamental Check with Prateek Agarwal, Head Equities, Bharti AXA Invest Manager

Pharmaceutical companies are seen posting a 40-50% growth in earnings for the July-September quarter from the same period last year, driven...